IRIS Accounts Production v24.1.0.578 07174392 Board of Directors 1.4.23 31.3.24 31.3.24 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh071743922023-03-31071743922024-03-31071743922023-04-012024-03-31071743922022-03-31071743922022-04-012023-03-31071743922023-03-3107174392ns15:EnglandWales2023-04-012024-03-3107174392ns14:PoundSterling2023-04-012024-03-3107174392ns10:Director12023-04-012024-03-3107174392ns10:PrivateLimitedCompanyLtd2023-04-012024-03-3107174392ns10:SmallEntities2023-04-012024-03-3107174392ns10:AuditExempt-NoAccountantsReport2023-04-012024-03-3107174392ns10:SmallCompaniesRegimeForDirectorsReport2023-04-012024-03-3107174392ns10:SmallCompaniesRegimeForAccounts2023-04-012024-03-3107174392ns10:FullAccounts2023-04-012024-03-3107174392ns10:Director22023-04-012024-03-3107174392ns10:RegisteredOffice2023-04-012024-03-3107174392ns5:CurrentFinancialInstruments2024-03-3107174392ns5:CurrentFinancialInstruments2023-03-3107174392ns5:ShareCapital2024-03-3107174392ns5:ShareCapital2023-03-3107174392ns5:RetainedEarningsAccumulatedLosses2024-03-3107174392ns5:RetainedEarningsAccumulatedLosses2023-03-3107174392ns5:PlantMachinery2023-04-012024-03-3107174392ns5:PlantMachinery2023-03-3107174392ns5:PlantMachinery2024-03-3107174392ns5:PlantMachinery2023-03-3107174392ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-03-3107174392ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-03-31
REGISTERED NUMBER: 07174392 (England and Wales)















Unaudited Financial Statements

for the Year Ended 31 March 2024

for

Sykes Oncology Ltd

Sykes Oncology Ltd (Registered number: 07174392)






Contents of the Financial Statements
for the Year Ended 31 March 2024




Page

Company Information 1

Statement of Financial Position 2

Notes to the Financial Statements 3


Sykes Oncology Ltd

Company Information
for the Year Ended 31 March 2024







DIRECTORS: Dr A J Sykes
Mrs L Sykes





REGISTERED OFFICE: 4 Carlton Road
Hale
Altrincham
Cheshire
WA15 8RJ





REGISTERED NUMBER: 07174392 (England and Wales)





ACCOUNTANTS: J Davenport & Co. Ltd
Chartered Accountants
East Meats
White Knowle
Chinley
Derbyshire
SK23 6EA

Sykes Oncology Ltd (Registered number: 07174392)

Statement of Financial Position
31 March 2024

31.3.24 31.3.23
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 4,046 4,296

CURRENT ASSETS
Debtors 5 5,085 1,891
Cash at bank and in hand 44,628 58,176
49,713 60,067
CREDITORS
Amounts falling due within one year 6 6,396 12,291
NET CURRENT ASSETS 43,317 47,776
TOTAL ASSETS LESS CURRENT
LIABILITIES

47,363

52,072

PROVISIONS FOR LIABILITIES 769 816
NET ASSETS 46,594 51,256

CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings 46,494 51,156
SHAREHOLDERS' FUNDS 46,594 51,256

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 4 November 2024 and were signed on its behalf by:



Dr A J Sykes - Director


Sykes Oncology Ltd (Registered number: 07174392)

Notes to the Financial Statements
for the Year Ended 31 March 2024

1. STATUTORY INFORMATION

Sykes Oncology Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Turnover
Revenue is recognised on the provision of medical services.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery - 25% on reducing balance

Financial instruments
Financial instruments are classified, and accounted for, according to the substance of the contractual arrangement, as either financial assets, financial liabilities or equity instruments.An equity instrument is any contract that evidences residual interest in the assets of the company after deducting all of its liabilities.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2023 - 2 ) .

Sykes Oncology Ltd (Registered number: 07174392)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2024

4. TANGIBLE FIXED ASSETS
Plant and
machinery
£   
COST
At 1 April 2023 9,847
Additions 1,099
At 31 March 2024 10,946
DEPRECIATION
At 1 April 2023 5,551
Charge for year 1,349
At 31 March 2024 6,900
NET BOOK VALUE
At 31 March 2024 4,046
At 31 March 2023 4,296

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.24 31.3.23
£    £   
Trade debtors 4,514 1,891
Tax 571 -
5,085 1,891

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.24 31.3.23
£    £   
Tax - 2,330
Directors' current accounts 3,269 5,326
Accrued expenses 3,127 4,635
6,396 12,291

7. RELATED PARTY DISCLOSURES

During the year, total dividends of £2,000 (2023 - £4,000) were paid to the directors .

At 31 March 2024 the company owed £3,269 (2023 £5,326) to the directors. No interest has been charged to the company in respect of this loan which is repayable on demand and classified in creditors due within one year.